Fiche centre
Research Site
Shenzhen — China
Essais liés9clinical trials
VilleShenzhenlocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07691970
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ravulizumab | Maladie rénale chronique | Phase 3 | NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | TERMINATED |
| Dapagliflozin | Maladie rénale chronique | Phase 4 | NCT06610526 | A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | ACTIVE_NOT_RECRUITING |
| Zibotentan/Dapagliflozin | Maladie rénale chronique | Phase 3 | NCT06087835 | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | ACTIVE_NOT_RECRUITING |
| Anifrolumab | Myopathies | Phase 3 | NCT07691970 | ROSY-S — Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment | RECRUITING |
| INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use | Lupus | À vérifier | NCT06314282 | INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use | RECRUITING |
| Baxdrostat/dapagliflozin | Hypertension | Phase 3 | NCT06742723 | BaxDuo-Pacific — A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure | RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT05138133 | IRIS — Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT07751848 | LOTUS — A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus | RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING |